QIAGEN NV Form 6-K November 14, 2011 <u>Table of Contents</u>

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 Commission File Number 0-28564

QIAGEN N.V.

Spoorstraat 50 5911 KJ Venlo The Netherlands

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F "

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): "

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): "

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes "No x

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

QIAGEN N.V. Form 6-K TABLE OF CONTENTS

Item	Page
Other Information	3
Signatures	4
Exhibit Index	5

OTHER INFORMATION

For the three- and nine-month periods ended September 30, 2011, QIAGEN N.V. prepared its quarterly report under United States generally accepted accounting principles (U.S. GAAP). This quarterly report is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

QIAGEN N.V.

BY:	/S/ ROLAND SACKERS
	Roland Sackers Chief Financial Officer
Date:	November 14, 2011
4	

EXHIBIT INDEX

Exhibit Exhibit No.

99.1 U.S. GAAP Quarterly Report for the Period Ended September 30, 2011

Exhibit 99.1 QIAGEN N.V. AND SUBSIDIARIES U.S. GAAP QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2011 TABLE OF CONTENTS

Financial Information

Condensed Consolidated Financial Statements

Condensed Consolidated Balance Sheets as of September 30, 2011 (unaudited) and December 31, 2010	<u>2</u>
Condensed Consolidated Statements of Income (unaudited) for the three months ended September 30, 2011 and 2010	<u>4</u>
Condensed Consolidated Statements of Income (unaudited) for the nine months ended September 30, 2011 and 2010	<u>5</u>
Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended September 30, 2011 and 2010	<u>6</u>
Condensed Consolidated Statements of Changes in Equity (unaudited) for the nine months ended September 30, 2011 and 2010	<u>7</u>
Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2011 and 2010	<u>8</u>
Notes to Condensed Consolidated Financial Statements (unaudited)	<u>9</u>
Operating and Financial Review and Prospects	<u>22</u>
Quantitative and Qualitative Disclosures About Market Risk	<u>28</u>
Recent Authoritative Pronouncements	<u>29</u>
Application of Critical Accounting Policies, Judgments and Estimates	<u>29</u>
Off-Balance Sheet Arrangements	<u>29</u>
Contractual Obligations	<u>29</u>
Legal Proceedings	<u>29</u>
Risk Factors	<u>30</u>

QIAGEN N.V. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in \$ thousands)

	Note	September 30, 2011 (unaudited)	December 31, 2010
Assets			
Current assets:			
Cash and cash equivalents		\$ 393,850	\$ 828,407
Short-term investments		92,497	106,077
Accounts receivable, net of allowance for doubtful accounts of \$4,319 and \$3,227 in 2011 and 2010, respectively		211,088	197,418
Income taxes receivable		14,011	10,920
Inventories, net	(10)	145,531	126,633
Prepaid expenses and other current assets		90,014	64,402
Deferred income taxes		26,717	30,731
Total current assets		973,708	1,364,588
Long-term assets:			
Property, plant and equipment, net		373,620	345,664
Goodwill	(11)	1,658,598	1,352,281
Intangible assets, net of accumulated amortization of \$392,446 and \$312,326 in 2011 and 2010, respectively	(11)	854,199	753,327
Deferred income taxes		20,910	37,182
Other assets		67,407	60,953
Total long-term assets		2,974,734	2,549,407
Total assets		\$ 3,948,442	\$ 3,913,995

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in \$ thousands, except par value)

	Note	September 30, 2011 (unaudited)	December 31, 2010	
Liabilities and equity				
Current liabilities:				
Accounts payable		\$ 44,900	\$ 47,803	
Accrued and other liabilities (of which \$10,329 and \$6,296 due to related	(15)	194,599	209,054	
parties in 2011 and 2010, respectively)	(13)	1)4,377	207,054	
Income taxes payable		21,179	25,211	
Current portion of long-term debt	(9)	351,661	75,835	
Deferred income taxes		35,841	30,504	
Total current liabilities		648,180	388,407	
Long-term Liabilities:				
Long-term debt, net of current portion (of which \$445,000 in 2011 and 2010	0 (9) (15)	446,505	797,171	
due to related parties)		010 501	200 (77	
Deferred income taxes		218,521	200,667	
Other liabilities		50,713	51,397	
Total long-term liabilities	(1.4)	715,739	1,049,235	
Commitments and contingencies	(14)			
Equity:				
Preference shares, 0.01 EUR par value, authorized—450,000 shares, no sha	res	_	_	
issued and outstanding				
Financing preference shares, 0.01 EUR par value, authorized—40,000 share	es,	_		
no shares issued and outstanding	and			
Common Shares, 0.01 EUR par value, authorized—410,000 shares, issued a outstanding—234,118 and 233,115 shares in 2011 and 2010, respectively	anu	2,738	2,724	
Additional paid-in capital		1,674,558	1,648,985	
Retained earnings		856,304	759,890	
Accumulated other comprehensive income	(13)	9,155	64,754	
Equity attributable to the owners of QIAGEN N.V.	(10)	2,542,755	2,476,353	
Noncontrolling interest		_,;;;_,;;;	_,.,0,000	
0				